From Yahoo Finance: 2025-05-06 10:09:00

Veraxa Biotech partners with OmniAb to develop bispecific antibody drug conjugate (bsADC) programme targeting solid tumors. The collaboration combines OmniAb’s antibody discovery solutions with Veraxa’s ADC linker technology. Veraxa will initiate a bsADC programme addressing two target molecules in cancer medicine using OmniAb’s antibody discovery solutions for high-quality leads. The resulting bsADC programme will be co-owned by both companies, sharing future revenues.

Veraxa focuses on developing antibody-based therapeutics, including bispecific T cell engagers and bispecific ADCs. The company is advancing its ADC pipeline and BiTAC formats towards clinical development. Veraxa is set to go public in the US through a merger with Voyager Acquisition Corp, expected to close in the fourth quarter of 2025. Strategic collaborations drive Veraxa’s pipeline growth strategy, with the OmniAb partnership being the second major initiative in the past six months.



Read more at Yahoo Finance: Veraxa and OmniAb to develop bispecific ADC tumour programme